Philip Sharp,MD

Radiation Oncologist Poor Joke Teller Omnia pro aegroto
#radonc
#lcsm
#pcsm
#bcsm

[Oak Ridge Lab @ORNL]

A newly discovered mineral has been named spanoite in honor of ORNL researcher Tyler Spano, recognizing her contributions to mineralogy.

Read the full story: https://t.co/SX2totrh49

[Oak Ridge Lab @ORNL]

At ORNL, science never sleeps.

Autonomous labs pair robots, advanced instruments, artificial intelligence and high-performance computing to assist scientists by speeding research results and insights.

Learn more about autonomous science at ORNL: https://t.co/Bvdq2vKhyk

[Susannah Ellsworth @free_radical28]

You could call this a “shocking” omission

Sorry I couldn’t “resist”

All kidding aside, in addition to the lack of sham controls, there are real questions about adequacy of the control arms, biologic plausibility of TTF, lack of reliable in vivo dosimetry (a huge potential confounder of outcomes) and regulatory environment which are discussed in depth in the article. Many thanks to @Timothee_MD for leading the project.

[Ash Paul @pash22]

Sham Controls and Tumor Treating Fields: Does the Ethical Argument Hold? via @Timothee_MD et al
https://t.co/3avzzeR8jt

[JAMA Oncology @JAMAOnc]

Adding consolidative thoracic radiotherapy to atezolizumab maintenance for extensive-stage small cell lung cancer led to more severe toxic effects, mainly infections, without survival benefit compared to atezolizumab alone. https://t.co/NQnMVhHGmk

[Tejas Patil @TejasPatilMD]

⭐️Very important study in ES-SCLC. What is role of consolidation thoracic radiotherapy in ES-SCLC?
😳No benefit in PFS or OS with consolidation XRT vs atezo alone. Trial stopped early due to toxicity.
👉🏽Given IMForte and potential DLL3 TCE maintenance options, careful pt selection needed for this approach.

@IyengarPuneeth @DrewMoghanaki @SclcSMASHERS @lcsmchat @OncoAlert

[Oak Ridge Lab @ORNL]

This gold cylinder is a dilution refrigerator used for quantum research.

Inside, experiments take place just fractions of a degree above absolute zero. It allows researchers to test ways to move information through light, a key step toward future quantum networks.

[PDBrown @PDBrownOnc]

Any benefit dose escalation IORT for GBM?
NO, according to this randomized trial with no PFS or OS benefit
https://t.co/PirGt5gvSN

[Oak Ridge Lab @ORNL]

ORNL's operations workforce builds and maintains the infrastructure that powers AI-enabled autonomous science, helping researchers accelerate discovery through robotics, automation and advanced research systems.

Read the story ⬇️
https://t.co/jGbJh3zDwE

[NonsparseOncologist @5_utr]

🧵 The 10-year FLAME results are important data, and one sentence in Methods deserves more attention than the headline bDFS numbers: “No additional toxicity outcomes were collected after 60 months.” A thread on what that means for a treatment now entered into standard practice

[Philip Sharp,MD @AtomicCityDoc]

@SprakerMDPhD @OncBrothers @BijoyTelivala @dr_yakupergun @RenoHemonc @NiuSanford @lauren_henke I have been doing LDRT for arthritis for the past 7 years. Initially, referrals were word of mouth. Now, by far, my top 3 referrings are orthopedists.

[Oncology Brothers @OncBrothers]

Is this widely adopted now? Can you share some data around this? Also, what has been your referral pattern for this (PCP? Ortho? Or Med Onc for isolated joint pain that's getting worse post ET… etc)? 🙏🙏

@BijoyTelivala @dr_yakupergun @RenoHemonc @NiuSanford @lauren_henke

[Matt Spraker @SprakerMDPhD]

@OncBrothers @BijoyTelivala @dr_yakupergun @RenoHemonc @NiuSanford @lauren_henke Our main referrings are PCP, family, sports med, rheumatology, pain, and ortho.

A lot of self referrals too, happy patients tell everyone in town.

[Matt Spraker @SprakerMDPhD]

@OncBrothers @BijoyTelivala @dr_yakupergun @RenoHemonc @NiuSanford @lauren_henke We have a large network practice and lately even Ortho has become a fan! 😎

It is a great treatment for many patients that live in pain with limited options.

At least one group is studying use with endocrine therapy, think it’s funded by an ASTRO grant? Maybe?

[Todd Scarbrough @toddscarbrough]

Just to provide some context

There is a great, lengthy chapter on this in the rad onc Brady and Perez textbook, 5th edition… that came out twenty years ago

Tens of thousands of people are treated each year across the globe (not in US obv), and have been for decades and decades (and decades)

About half of all US academic depts claimed to offer the tx per an ACR survey ~40 years ago

The history of all of it is weirdly fascinating

[Evan Thomas MD/PhD @EvanThomas84]

We are now live on https://t.co/T5Qleq254g.

https://t.co/5OY0k0B96f

💪

[Yakup Ergün @dr_yakupergun]

A clearly problematic study has now lost its status as valid scientific evidence. After the Nature Medicine retraction, the related ASCO abstract was also retracted from JCO.

Retractions are no longer rare, but seeing a meeting abstract formally retracted is still not a common occurrence. Hopefully, this case will serve as a lesson.

[Advances, an ASTRO Journal @Advances_ASTRO]

Does the addition of mucosal ☢️ impact outcomes in patients with #hncsm carcinoma of unknown primary (CUP) site?

This retrospective analysis compared outcomes in pts w/ SCC CUP treated with (n=46) and without (n=88) 50 Gy ☢️ to putative mucosal sites. From mFU 72 mo:
➡️ 5yr OS with and without mucosal ☢️was similar: 56.1% and 57.5%, respectively (p=0.899)
➡️ Tumor recurrences with and without mucosal ☢️ were similar: 32.6% and 27.3%, respectively (p=0.591)
➡️ All mucosal recurrences (9.7%) occurred in current 🚬 at >3 yrs post initial diagnosis, suggestive of 2nd primary tumor

🔗 - https://t.co/IxTpqfFlck
#radonc @ASTRO_org

[PDBrown @PDBrownOnc]

Update Randomized trial Temozolomide vs Radiotherapy Low Grade Glioma
NO diff PFS/OS btwn study arms
NOTE: poor results compared to RTOG 9802 RT+PCV Median OS 13 yr
RT+chemo is standard of care (NOT single modality) https://t.co/UPKliCJX6Q

[Dr. Nina Niu Sanford @NiuSanford]

Important survivorship data for anal SCC. Definitive chemoRT achieves cure in most, but w substantial functional cost. In PRO study, 62% of pts w/o stoma had major LARS.

De-escalation RCTs (DECREASE fully accrued, PLATO-ACT4 w early results) critical for improving QOL @OncoAlert